Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Spinal Muscular Atrophy Type 2: full-pipeline trial registry
1 of 4 indexed Spinal Muscular Atrophy Type 2 trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Spinal Muscular Atrophy Type 2: 4 US clinical trials tracked, 1 recruiting.
Spinal Muscular Atrophy Type 2 is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Scholar Rock, running 4 of these trials.
Enrollment posture brief
Registry condition spinal-muscular-atrophy-type-2
OPEN 1 | RECR 25% | LATE 2 | EARLY 2 | RANK #4115 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Spinal Muscular Atrophy Type 2 lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Spinal Muscular Atrophy Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Spinal Muscular Atrophy Type 2 is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Scholar Rock
NCT07047144
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
Scholar Rock
NCT05626855
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Scholar Rock
NCT05156320
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Scholar Rock
NCT03921528
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Spinal Muscular Atrophy Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Spinal Muscular Atrophy Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Spinal Muscular Atrophy Type 2 page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Spinal Muscular Atrophy Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Scholar Rock sponsors the most Spinal Muscular Atrophy Type 2 trials on record, review their full trial history before evaluating a specific study. See Scholar Rock's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Spinal Muscular Atrophy Type 2 condition card totals 4 registered trials; most-linked intervention Apitegromab; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.